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Abstract
Background: Recently, evidence has emerged that palliative gastrectomy in patients with stage IV gastric cancer
may offer some survival benefits. However, the decision whether to perform primary tumor surgery remains
challenging for surgeons, and investigations into models that are predictive of prognosis are scarce. Current study
aimed to develop and validate prognostic nomograms for patients with metastatic gastric adenocarcinoma treated
with palliative gastrectomy.
Methods: The development dataset comprised 1186 patients from the Surveillance, Epidemiology, and End Results
Program who were diagnosed with metastatic gastric adenocarcinoma in 2004–2011, while the validation dataset
included 407 patients diagnosed in 2012–2015. Variables were incorporated into a Cox proportional hazards model
to identify independent risk factors for survival. Both pre- and postoperative nomograms for predicting 1- or 2-year
survival probabilities were constructed using the development dataset. The concordance index (c-index) and
calibration curves were plotted to determine the accuracy of the nomogram models. Finally, the cut-off value of
the calculated total scores based on preoperative nomograms was set and validated by comparing survival with
contemporary cases without primary tumor surgery.
Results: Age, tumor size, location, grade, T stage, N stage, metastatic site, scope of gastrectomy, number of examined
lymph node(s), chemotherapy and radiotherapy were risk factors of survival and were included as variables in the
postoperative nomogram; the c-indices of the development and validation datasets were 0.701 (95% confidence
interval [CI]: 0.693–0.710) and 0.699 (95% CI: 0.682–0.716), respectively. The preoperative nomogram incorporated age,
tumor size, location, grade, depth of invasion, regional lymph node(s) status, and metastatic site. The c-indices for the
internal (bootstrap) and external validation sets were 0.629 (95% CI: 0.620–0.639) and 0.607 (95% CI: 0.588–0.626),
respectively. Based on the preoperative nomogram, patients with preoperative total score > 28 showed no survival
benefit with gastrectomy compared to no primary tumor surgery.
Conclusions: Our survival nomograms for patients with metastatic gastric adenocarcinoma undergoing palliative
gastrectomy can assist surgeons in treatment decision-making and prognostication.
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Background
Gastric cancer is one of the leading causes of cancer-
related mortality worldwide [1]. Adenocarcinoma ac-
counts for the majority of gastric cancer diagnoses, and
patients with gastric adenocarcinoma often experience
relatively short survival times. Surgery provides a
curative opportunity for a number of patients and is
considered the foundation of multimodal management
of gastric cancer. However, a substantial proportion of
gastric adenocarcinomas are advanced or metastatic
disease at the time of diagnosis. Surgery is generally not
a priority recommendation in such circumstances,
except for patients with potentially life-threatening
complications such as gastrointestinal bleeding, perfor-
ation, or obstruction.
A randomized clinical trial REGATTA which aimed
to evaluate whether the addition of gastrectomy to
chemotherapy improves survival for advanced gastric
cancer patients with a single non-curable factor was
terminated ahead of time due to the negative results
from the interim analysis [2]. However, retrospective
studies have produced evidence of a potential benefit to
palliative gastrectomy in patients with stage IV gastric
cancer [3–8]. A previous systematic review and meta-
analysis of 14 studies comprising 3003 patients with in-
curable advanced gastric cancer revealed that palliative
gastrectomy significantly improved overall survival [9].
Moreover, a recent study based on the Surveillance,
Epidemiology, and End Results Program (SEER) data
demonstrated a survival benefit for palliative gastrec-
tomy in gastric cancer patients with stage IV disease
after balancing baseline characteristics using propensity
score matching analysis [10]. Results derived from non-
consecutive studies demonstrated that patients who
were younger, had better preoperative nutritional sta-
tus, exhibited less nodal involvement, and underwent
postoperative chemotherapy often experienced better
outcomes [8]. Palliative primary tumor resection also
offers advantages to patients with normal levels of
serum carcinoembryonic antigen and/or normal CA19–
9 [7], as well as to those with metastases confined to a
single site [3].
However, the decision regarding whether to perform
primary tumor surgery remains challenging, and in-
vestigations into models that are predictive of progno-
sis are scarce. As such, there is a need to identify and
appraise factors that predict the outcomes of palliative
gastrectomy in patients with metastases at the time of
initial diagnosis of gastric adenocarcinoma, either for
predicting the individuals’ prognoses or for clinical
decision-making. Therefore, we performed this study
using the SEER database to construct nomograms that
predict the survival of patients with metastatic gastric
adenocarcinoma subsequent to palliative gastrectomy.
Methods
Database and patient selection
The recently released SEER database submission [Incidence
- SEER 18 Regs Custom Data (with additional treatment
fields), Nov 2017 Sub] includes cancer patients diagnosed
from 1973 to 2015. We accessed the database using the
SEER*Stat software version 8.3.5 (National Cancer Institute,
USA) with permission from the SEER program office.
There were 16,588 patients with metastatic gastric adeno-
carcinoma (International Classification of Diseases for On-
cology-3 histologic type/behavior code: 8140/3–8389/3) in
the database who were diagnosed between 2004 and 2015.
Of these patients, 1971 were known to have been under-
gone a gastrectomy and 14,344 had not had surgery on the
primary tumor. After excluding patients with missing es-
sential data, 1593 patients with advanced gastric adenocar-
cinoma (i.e., with distant metastases at presentation) who
received palliative gastrectomy were analyzed; 1186 patients
(approximately three-quarters of the dataset) who were di-
agnosed between 2004 and 2011 were used as the develop-
ment cohort to construct predictive models, while the
remaining 407 patients (who were diagnosed between 2012
and 2015) were used as the validation cohort. Figure 1
shows the flowchart of data selection.
Recoding and transformation of variables
Some variables in the original dataset were re-coded for
purposes of statistical analysis. Tumors located in the fun-
dus and body of the stomach, gastric antrum, pylorus, and
lesser or greater curvature of stomach were re-classified as
non-cardia tumors. Consequently, the primary lesion sites
were categorized as “cardia tumors”, “non-cardia tumors”,
“overlapping lesions”, and “stomach, not otherwise speci-
fied (NOS)”. Because relatively few patients had well-dif-
ferentiated (grade [G]1) and undifferentiated (G4) tumors,
they were combined with patients with moderately differ-
entiated tumors (G2) and poorly differentiated tumors
(G3), respectively, and the tumor grades were thus re-clas-
sified as G1/2 and G3/4. Because patient records spanned
more than 10 years, staging according to both the Ameri-
can Joint Committee on Cancer (AJCC) sixth and seventh
editions coexisted in the dataset; therefore, we translated
the AJCC sixth edition T and N staging codes into their
corresponding seventh edition codes to generate a uni-
form dataset.
Three continuous variables, “age at diagnosis”, “tumor
size”, and “number of regional lymph nodes examined”
were transformed into categorical variables. The X-tile
plotting software was used to determine the cut-off value
for continuous variables in terms of their impact on
survival [11]. The analysis of the development dataset
revealed that patients with more than 10 lymph nodes
examined during surgery had significantly superior
survival rates compared to those who had fewer than 10
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lymph nodes examined. Similarly, survival curves were
also separated into three age groups divided by two cut-
off points: 65 and 80 years, as well as three prognostic
groups by two tumor size cut-off points: 30 and 50mm.
Therefore, in the final Cox proportional hazards models
and nomograms, tumor size was presented as three
subgroups: “≤30 mm”, “31-50 mm”, and “> 50mm”. Age
was presented as “≤65 years”, “66–80 years”, and “> 80
years”. The number of regional lymph nodes examined
was divided into the “≤10” and “> 10” groups.
Construction of nomograms
The development dataset (i.e., patients diagnosed be-
tween 2004 and 2011) was used to construct the nomo-
grams. Parameters that were patient-related (age, sex,
and race), tumor-related (tumor size, location, patho-
logical subtype, grade, T stage, N stage, and metastatic
site), and treatment-related (scope of gastrectomy, exam-
ined lymph nodes, surgery to other sites, chemotherapy,
and radiotherapy) were included in the Cox regression
analysis. Cox regression was performed using SPSS 22.0
statistical software (IBM Corp., Armonk, NY). The back-
ward stepwise method, including parameters with P-
values < 0.01 and excluding those with P-values > 0.10,
was used in combination with multivariate Cox propor-
tional hazards regression analysis to select prognosis
predictive variables for the nomogram. The results were
described as hazards ratios (HRs) and 95% confidence
intervals (CIs). All P-values were 2-tailed, and values of
less than 0.05 were considered statistically significant.
We hypothesized that survival can be predicted pre-
operatively in patients who underwent palliative gastrec-
tomy; hence, a preoperative model was constructed. This
model incorporated “age at diagnosis”, “sex”, “race”,
“grade”, “tumor size”, “tumor location”, “pathological
subtype”, “tumor invasion” (according to T stage), “re-
gional LN(s) status” (negative or positive, according to N
stage) and “metastatic sites” into Cox regression
analyses. It was assumed that these parameters could be
evaluable pre-surgically. Although “T stage” and “N
stage” are generally derived from postoperative patho-
logical findings, modern imaging techniques can pro-
duce accurate staging algorithms, at least for negative or
positive regional lymph node (LN) status.
Two nomograms were devised based on the above
Cox models by scoring the independent variables
according to the regression coefficient. Nomograms were
plotted using the “nomogram” function in ‘R’ version
3.5.0 (The R Foundation for Statistical Computing,
Vienna, Austria) using the ‘rms’ and ‘survival packages’
(http://www.r-project.org/).
Validation of nomograms
The accuracies of the nomogram models were assessed
using discrimination and calibration. Discrimination is
the ability of the models to separate patients according
to their survival status, and was measured using the
Harrell concordance index (c-index). Similar to the area
under the receiver operating characteristic curve, the c-
index estimates the probability of concordance between
predicted and observed outcomes in rank order and
ranges between 0.5 and 1.0; higher values indicate better
discrimination. Calibration refers to the discrepancy
between predictions and actual outcomes, and is usually
measured by graphic calibration curves that represent
the relationship between the observed outcome frequen-
cies and predicted probabilities.
The validation procedures were also performed using
‘R’ version 3.5.0. For internal validation of predictive
models, 1000 bootstraps with sample sizes of 200 were
Fig. 1 Flowchart of data selection. SEER, Surveillance, Epidemiology, and End Results Program
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generated from the original dataset. We calculated
c-indices and plot calibration curves to compare the
nomogram-predicted 1-year and 2-year survival prob-
abilities with the actually-observed survival outcomes.
Plots that approached a 45-degree line indicate a well-
calibrated nomogram. The external validation dataset
comprised patients diagnosed during a different period
(2012–2015), and 1000 times bootstrapping (size 130)
was performed to calculate and plot the calibration
curves.
Results
Characteristics of patients in the datasets
The development dataset comprised 1186 patients diag-
nosed between 2004 and 2011, while the validation data-
set included 407 patients diagnosed between 2012 and
2015. Table 1 shows the demographic, clinical, patho-
logical, and treatment-related characteristics of the
patients in this study. Patients older than 65 years
accounted for 56.2% of the development cohort, with a
median age 68 years old; 66.2% were male and 64.3%
were Caucasian-Americans. Intestinal and diffuse sub-
type accounted for 18.5 and 8.9%, 72.6% patients were
other adenocarcinoma or NOS. Most tumors (875 or
73.8%) were poorly differentiated (G3) or undifferenti-
ated (G4). More than half (56.7%) of the primary tumors
in the stomach penetrated the serosa (T4a) or invaded
adjacent structures (T4b). Pure distant lymph node
metastasis were found in 208 patients (17.5%), while 839
(70.7%) had synchronous visceral metastasis (i.e., distant
metastases other than positive distant lymph nodes,
carcinomatosis, Krukenberg tumors [metastases to the
ovaries], or malignant ascites). Only 278 patients (23.4%)
received total or near-total gastrectomy. The median
number of examined regional lymph nodes was 12, with
metastases noted in 1044 patients (88.0%). The charac-
teristics of the patients in the validation cohort were
largely similar to those of patients in the development
cohort.
Cox regression models
Fifteen parameters were initially incorporated the into Cox
regression analyses, including three demographic variables,
seven tumor-related variables, and five treatment-related
variables (Postoperative Model); the analysis results are
shown in Table 2. T and N staging were consistently signifi-
cant prognostic factors. Except for T2 tumors with a statis-
tically insignificant increased risk of death, the risk of death
in patients with ≥T3 tumors was approximately 2-fold
greater than in those with T1 tumors, with HRs of 1.9 (95%
CI: 1.3–2.7), 2.3 (95% CI: 1.6–3.3), and 2.5 (95% CI: 1.7–
3.5) for T3, T4a, and T4b tumors, respectively (all P < 0.05).
The risk of death was also greater in patients with ≥N1
tumors than in those with N0 tumors; moreover, older age
and poorer tumor differentiation were also associated with
poorer survival. However, patients with only distant lymph
node involvement had a significantly lower risk of death
than patients with metastases at other sites; non-cardia
tumors showed a lower risk of death than cardia tumors.
Chemotherapy and radiotherapy significantly decreased the
risk of death with HRs of 0.5 (95% CI: 0.4–0.6) and 0.8
(95% CI: 0.6–0.9). Sex, race, pathological subtype and sur-
gery to other site(s) or node(s) did not have a significant
impact on survival. Tumor size > 50mm was associated
with a marginally decreased risk of death compared to the
“≤30mm” group (HR: 0.8, 95%CI: 0.7–1.0, P = 0.069). Based
on the backward stepwise method, “age”, “tumor size”,
“tumor location”, “grade”, “T stage”, “N stage”, “metastatic
site”, “scope of gastrectomy”, “number of examined lymph
node(s)”, “chemotherapy” and “radiotherapy” were retained
in the final regression equation.
In the preoperative Cox regression model, older age,
poorer differentiation, deeper tumor invasion, and posi-
tive regional LN(s) were shown to increase the risk of
death significantly. Pure distant LN(s) metastasis had a
lower risk of death than metastases in other site(s). After
performing the backward stepwise procedure, the above
variables together with tumor location and tumor size
were retained in the final regression equation. The
results were also shown in Table 2.
Postoperative nomogram and validation
After running the R program, we plotted a nomogram
for the determination of postoperative prognosis (Fig. 2).
Eleven parameters were scored using various points
within a scale of 1 to 10 as follows: age at diagnosis (0
for age ≤ 65 years, 0.9 for age 66–80 years, and 3.8 for
age > 80 years), tumor location (0 for non-cardia tumor,
2.6 for cardia tumor, 2.8 for overlapping lesion, and 2.4
for NOS), tumor size (0 for > 50mm, 2.0 for ≤30mm,
and 1.8 for 31-50 mm), grade (0 for grade 1/2 and 3.0
for grade 3/4), T invasion (0, 3.9, 7.2, 9.2, and 10.0 for
T1, T2, T3, T4a, and T4b, respectively), N group (0, 3.2,
7.6, and 8.0 for N0, N1, N2, and N3, respectively), meta-
static site (0, 4.3, 6.6, and 5.6 for “distant lymph node
metastasis”, “visceral metastasis”, “visceral plus distant
lymph node metastasis”, and “distant metastasis, NOS”,
respectively), the number of examined regional lymph
nodes (0 for > 10 and 4.2 for ≤10), scope of gastrectomy
(0 for total or near total, 2.0 for partial, and 1.3 for gas-
trectomy, NOS), chemotherapy (0 for yes, 7.4 for no/un-
known), and radiotherapy (0 for yes, 2.8 for no/
unknown). The total above scores were summed to cal-
culate the individuals’ 1-year and 2-year survival rates.
The c-index for the postoperative nomogram model ob-
tained by bootstrap resampling was 0.701 (95% CI:
0.693–0.710). Bootstrap validation was performed to plot
the nomogram-predicted 1-year and 2-year survival
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probabilities against the corresponding observed sur-
vival rates obtained by the Kaplan-Meier method; the
calibration curves for the postoperative model are
shown in Fig. 3a. When applying the postoperative
nomogram to the validation dataset, the c-index was
0.699 (95% CI: 0.682–0.716); the calibration curves
are illustrated in Fig. 3b. The results indicated moder-
ate discrimination and good calibration for the model
in the validation cohort.
Table 1 Demographic, clinical, pathological, and surgical
characteristics of the patients
Variables Total population
[n (%),
n = 1593]
Development
set [n (%),
n = 1186]
Validation
set
[n (%),
n = 407]
Age [median (IQRa)] 67.0 (57.0, 77.0) 68.0 (57.0,
77.0)
66.0
(55.0,
77.0)
≤65 715 (44.9) 520 (43.8) 195 (47.9)
66–80 644 (40.4) 492 (41.5) 152 (37.3)
> 80 234 (14.7) 174 (14.7) 60 (14.7)
Sex
Male 1032 (64.8) 785 (66.2) 247 (60.7)
Female 561 (35.2) 401 (33.8) 160 (39.3)
Race
White 1014 (63.7) 763 (64.3) 251 (61.7)
Black 240 (15.1) 181 (15.3) 59 (14.5)
Other 339 (21.3) 242 (20.4) 97 (23.8)
Tumor location
Cardia 269 (16.9) 213 (18.0) 56 (13.8)
Non-cardia 998 (62.6) 738 (62.2) 260 (63.9)
Overlapping lesion 182 (11.4) 128 (10.8) 54 (13.3)
Stomach, NOSb 144 (9.0) 107 (9.0) 37 (9.1)
Tumor size (mm)
[median (IQR)]
55.0 (40.0, 80.0) 55.0 (40.0,
80.0)
58.0
(40.0,
80.0)
≤30 230 (14.4) 172 (14.5) 58 (14.3)
31–50 466 (29.3) 343 (28.9) 123 (30.2)
>50 897 (56.3) 671 (56.6) 226 (55.5)
Pathological subtype
Intestinal type 317 (19.9) 219 (18.5) 98 (24.1)
Diffuse type 167 (10.5) 106 (8.9) 61 (15.0)
Adenocarcinoma,
NOS
959 (60.2) 754 (63.6) 205 (50.4)
Other adenocarcinoma 150 (9.4) 107 (9.0) 43 (10.6)
Grade
Grade1/2 425 (26.7) 311 (26.2) 114 (28.0)
Grade3/4 1168 (73.3) 875 (73.8) 293 (72.0)
T stage (AJCCc 7th)
T1 73 (4.6) 55 (4.6) 18 (4.4)
T2 79 (5.0) 49 (4.1) 30 (7.4)
T3 519 (32.6) 409 (34.5) 110 (27.0)
T4a 577 (36.2) 402 (33.9) 175 (43.0)
T4b 345 (21.7) 271 (22.8) 74 (18.2)
N stage (AJCC 7th)
N0 202 (12.7) 142 (12.0) 60 (14.7)
N1 706 (44.3) 522 (44.0) 184 (45.2)
N2 458 (28.8) 349 (29.4) 109 (26.8)
Table 1 Demographic, clinical, pathological, and surgical
characteristics of the patients (Continued)
Variables Total population
[n (%),
n = 1593]
Development
set [n (%),
n = 1186]
Validation
set
[n (%),
n = 407]
N3 227 (14.2) 173 (14.6) 54 (13.3)
Metastatic site(s)
Distant LN(s)d 276 (17.3) 208 (17.5) 68 (16.7)
Viscera 1121 (70.4) 839 (70.7) 282 (69.3)
Viscera plus distant
LN(s)
118 (7.4) 96 (8.1) 22 (5.4)
Distant metastasis,
NOS
78 (4.9) 43 (3.6) 35 (8.6)
Gastrectomy
Partial gastrectomy 808 (50.7) 612 (51.6) 196 (48.2)
Near-total or total
gastrectomy
361 (22.7) 278 (23.4) 83 (20.4)
Gastrectomy, NOS 424 (26.6) 296 (25.0) 128 (31.4)
No. of regional LN(s)
examined [median (IQR)]
13 (6, 21) 12 (6, 20) 14 (7, 22)
≤10 660 (41.4) 518 (43.7) 142 (34.9)
>10 933 (58.6) 668 (56.3) 265 (65.1)
Surgery to other site(s)
or node(s)
Yes 404 (25.4) 309 (26.1) 95 (23.3)
No 1189 (74.6) 877 (73.9) 312 (76.7)
Chemotherapy
Yes 802 (50.3) 579 (48.8) 223 (54.8)
No/Unknown 791 (49.7) 607 (51.2) 184 (45.2)
Radiotherapy
Yes 254 (15.9) 192 (16.2) 62 (15.2)
No/Unknown 1339 (84.1) 994 (83.8) 345 (84.8)
Sequence of radiotherapy
with surgery
Pre-operative
radiotherapy
69/254 (27.2) 37/192 (19.3) 32/62
(51.6)
Post-operative
radiotherapy
182/254 (71.7) 153/192
(79.7)
29/62
(46.8)
Intraoperative or
sandwich
3/254 (1.2) 2/192 (1.0) 1/62 (1.6)
ainterquartile range; bnot otherwise specified; cAmerican Joint Committee on
Cancer; dlymph node(s)
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Table 2 Multivariate Cox proportional hazards regression analysis of the development cohort
Postoperative Model Preoperative Model
HRa 95% CIb P HR 95% CI P
Age (“≤65”as reference) 0.004 0.000
66–80 1.075 0.935–1.236 0.311 1.285 1.123–1.470 0.000
>80 1.391 1.143–1.694 0.001 1.977 1.643–2.378 0.000
Sex (“Male” as reference)
Female 0.961 0.843–1.095 0.548 0.990 0.869–1.129 0.885
Race (“White” as reference) 0.600 0.593
Black 0.984 0.823–1.177 0.863 0.962 0.805–1.148 0.665
Other 0.923 0.789–1.079 0.313 0.923 0.791–1.078 0.314
Tumor location (“Cardia” as reference) 0.008 0.020
Non-cardia 0.816 0.684–0.974 0.024 0.935 0.785–1.113 0.449
Overlapping lesion 1.054 0.829–1.340 0.669 1.241 0.977–1.577 0.077
Stomach, NOSc 1.014 0.784–1.312 0.915 1.129 0.876–1.455 0.348
Tumor size (“≤30 mm” as reference) 0.033 0.041
31-50mm 0.985 0.802–1.209 0.882 1.120 0.914–1.373 0.273
> 50 mm 0.833 0.684–1.014 0.069 0.938 0.773–1.138 0.515
Subtype (“Intestinal type” as reference) 0.536 0.267
Diffuse type 0.861 0.664–1.117 0.260 0.925 0.717–1.193 0.547
Adenocarcinoma, NOS 0.997 0.846–1.175 0.972 1.095 0.932–1.287 0.269
Other adenocarcinoma 0.906 0.708–1.159 0.431 0.943 0.738–1.206 0.642
Grade (“Grade1/2” as reference)
Grade3/4 1.334 1.155–1.540 0.000 1.269 1.100–1.463 0.001
T category-AJCCd 7th (“T1” as reference) 0.000 0.000
T2 1.395 0.894–2.179 0.143 1.252 0.803–1.953 0.321
T3 1.906 1.341–2.708 0.000 1.658 1.171–2.348 0.004
T4a 2.284 1.594–3.273 0.000 1.971 1.382–2.811 0.000
T4b 2.457 1.704–3.542 0.000 2.128 1.481–3.058 0.000
N category-AJCC 7th (“N0” as reference) 0.000
N1 1.341 1.082–1.662 0.007 – – –
N2 2.003 1.579–2.542 0.000 – – –
N3 2.128 1.617–2.801 0.000 – – –
N+ – – – 1.397 1.137–1.717 0.001
Metastatic site(s) (“Distant LN(s)e” as
reference)
0.000 0.000
Viscera 1.496 1.255–1.783 0.000 1.586 1.334–1.886 0.000
Viscera plus distant LN(s) 1.810 1.389–2.359 0.000 1.782 1.372–2.314 0.000
Distant metastasis, NOS 1.748 1.223–2.497 0.002 1.664 1.173–2.362 0.004
Gastrectomy (“Partial gastrectomy” as
reference)
0.078
Near-total or total gastrectomy 0.838 0.718–0.978 0.025 – – –
Gastrectomy, NOS 0.930 0.801–1.080 0.343 – – –
No. of regional LN(s) examined (“≤10”
as reference)
> 10 0.684 0.591–0.792 0.000 – – –
Surgery to other site(s) or node(s) (“No”
as reference
Ma et al. BMC Cancer          (2019) 19:852 Page 6 of 11
Preoperative nomogram and validation
A similar procedure to the above was performed to gen-
erate a preoperative nomogram based on a preoperative
model (Fig. 4), which was designed to predict prognoses
before making surgical decisions. Seven preoperatively
measurable predictors and assigned scores of the values
were as following: age ≤ 65, 66–80, and ≥ 80 years were
scored as 0, 3.5, and 9.1 points, respectively; non-cardia
tumor was scored as 0, while cardia tumor, overlapping
lesion and tumor, NOS were scored as 1.5, 3.6, 2.6 re-
spectively; tumor > 50 mm was scored as 0, ≤30 mm was
scored as 1.0 and 31-50 mm was scored as 2.4; grades 1/
2 and 3/4 were scored as 0 and 2.9 points; “T1”, “T2”,
“T3”, “T4a”, and “T4b” were scored as 0, 3.3, 6.8, 9.0,
and 10.0 points, respectively; negative regional LN(s)
and positive regional LN(s) was scored as 0 and 4.3. As
for sites of metastasis, “distant lymph node-only
metastasis” was scored as 0, “visceral metastasis” as 5.7,
“visceral plus distant lymph node metastasis” as 7.4, and
“distant metastasis, NOS” as 6.1. The c-index of the
postoperative nomogram using bootstrap and external
validation were 0.629 (95% CI: 0.620–0.639) and 0.607
(95% CI: 0.588–0.626) respectively. Figure 3c and d
shows the calibration curves of the predicted 1-year and
2-year survival probabilities versus actual survival rates
based on bootstrap resampling and validation data.
Determination of cut-off value for preoperative
nomogram score
Cases in the development dataset were scored base on
preoperative nomogram, and total scores were calcu-
lated. A cut-off value was attempted several times manu-
ally by comparing survival with that of contemporarily
registered cases with no primary tumor surgery. A total
Table 2 Multivariate Cox proportional hazards regression analysis of the development cohort (Continued)
Postoperative Model Preoperative Model
HRa 95% CIb P HR 95% CI P
Yes 1.008 0.877–1.159 0.913 – – –
Chemotherapy (“No/Unknown” as
reference
Yes 0.514 0.448–0.589 0.000 – – –
Radiotherapy (“No/Unknown” as
reference
Yes 0.778 0.647–0.936 0.008 – – –
ahazard ratio; bconfidence interval; cnot otherwise specified; dAmerican Joint Committee on Cancer; elymph node(s)
Fig. 2 Postoperative prognostic nomogram for patients with metastatic gastric adenocarcinoma who undergo palliative gastrectomy. Visceral
metastasis is defined as distant metastasis other than positive distant lymph nodes, carcinomatosis, Krukenberg tumors (metastases to the
ovaries), or malignant (tumor cell-positive) ascites. AJCC, American Joint Committee on Cancer; NOS, not otherwise specified; LN, lymph node
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score of 28 was found to be an optimal cut-off point.
After setting the “no primary tumor surgery group” as
reference in the Cox regression, there was no survival
benefit for patients with a total score > 28 (HR = 0.877,
95% CI: 0.761–1.011, P = 0.071). In fact, survival for
patients with a total score ≤ 28 was shown to be superior
to the “no primary tumor surgery group” (HR = 0.512,
95%CI: 0.477–0.550, P = 0.000); survival curves are
showed in Fig. 5a. We then applied the scoring system
in the preoperative nomogram to the validation dataset.
Patients in the validation dataset were divided into two
groups based on a total score ≤ 28 and a total score > 28,
while comparing survival to that of the “no primary
tumor surgery group” (contemporarily registered). The
group with a total score > 28 showed no survival benefit
[median overall survival (mOS): 5.0 (3.0–7.0) vs. 5.0
(4.7–5.3) months, HR: 1.031(95% CI: 0.758–1.403), P =
0.844). Those with a total score ≤ 28 group showed im-
proved survival (mOS: 12.0 (10.1–13.8) vs. 5.0 (4.7–5.3)
months, HR: 0.540 (95% CI: 0.473–0.616), P = 0.000);
survival curves are showed in Fig. 5b.
Discussion
A staging-guided treatment strategy is the mainstay of
clinical management for the vast majority of cancer pa-
tients. Evidence exists for supporting primary site surgery
in patients with various stage IV cancers such as renal
cancer [12, 13], breast cancer [14, 15], and colorectal can-
cer [16, 17]. It was suggested that resection of the primary
tumor could potentially reduce the immunosuppressive
tumor burden or remove the source of new metastases
[18]. Although the REGATTA study failed to demonstrate
survival benefit of palliative gastrectomy plus chemother-
apy in advanced gastric cancer patients [2]. Results of
retrospective SEER database analysis prone to benefit of
palliative gastrectomy [10]. In fact, in REGATTA study,
about one-third tumors located in upper third of stomach
in gastrectomy plus chemotherapy group, while cardia
Fig. 3 Calibration curves for the nomograms for patients with metastatic gastric adenocarcinoma who undergo palliative gastrectomy. a:
Bootstrap validation of postoperative prognostic nomogram with samples sizes of 200 in the development dataset. b: External validation of
postoperative prognostic nomogram using the cohort of 407 patients with samples sizes of 130. c: Bootstrap validation of preoperative
nomogram with samples size of 200 in the development dataset. d: External validation of preoperative nomogram using the 407-patient
validation cohort. The 45-degree grey lines show the ideal reference lines where the predicted survival probabilities match the actual survival
proportions. Dots indicate the predicted probabilities for the resampled groups of patients with their respective 95% confidence intervals
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tumor accounted for only 16.9% in current SEER dataset.
This may explain the disappointment results of RE-
GATTA. We considered that selected patients with
advanced gastric adenocarcinoma could benefit from
palliative gastrectomy. We therefore developed prognostic
nomograms aimed at identifying patients who would
benefit from this procedure; our models will be helpful for
individuals’ risk determination and clinical decision-
making.
Most of the studies mentioned above that demonstrated
survival benefit of palliative gastrectomy were conducted
in Asian countries, but given the paucity of cases of meta-
static gastric cancer with palliative gastrectomy in clinical
practices, a retrospective analysis in single center is diffi-
cult to conduct. In addition, analysis based on the SEER
data demonstrated a survival benefit for palliative gastrec-
tomy in stage IV gastric cancer patients [10]. We selected
the SEER database, which included only American cases,
in current study. And the results of this analysis are not
necessarily transferable to Asian patients.
The postoperative nomogram provided individualized
estimates of overall survival for patients with metastatic
gastric adenocarcinoma who received palliative gastrec-
tomy. Similar to lymph node dissection for operable
diseases [19], this nomogram as well as the findings of
another study [20] showed that regional lymph node
dissection during palliative surgery has a marked impact
on survival. Therefore, we strongly recommend extensive
lymph node dissection, such as D2 lymphadenectomy,
even during palliative gastrectomy.
Other than patients who develop emergency complica-
tions, surgeons occasionally face a dilemma regarding
whether to perform gastrectomy on gastric cancer patients
with metastases present at the time of initial diagnosis,
especially those with supposedly more favorable prognostic
factors, such as good performance status or single/oligome-
tastases. Our preoperative nomogram should be useful in
such circumstances. Although there remains no consensus
regarding preoperative T and N staging for gastric cancer,
we hold that evolving imaging modalities such as abdom-
inal multi-detector row computed tomography (with iso-
tropic or 3-dimensional imaging) [21], 3-Tesla magnetic
resonance imaging [22], endoscopic ultrasonography with
aspiration cytology [23, 24], or their combinations are likely
to provide increasingly precise estimation for tumor inva-
sion and lymph node status. By using some preoperatively
measurable variables, the preoperative nomogram could, to
a limited extent, help surgeons to make an appropriate
decision, since patients with total scores more than 28
showed no benefit from palliative gastrectomy.
There are some limitations associated with nomo-
grams such as ours. First, the validation cohort had simi-
lar characteristics to the development cohort, which
restricted the extrapolation to more diverse patient
groups. Ideally, such nomograms should be validated in
an external cohort or using data from other institutions.
Second, our nomograms showed moderate predictive
capabilities, especially for the preoperative nomogram
with c-indices no greater than 0.7. One possible explan-
ation was that the parameters used to construct the
Fig. 4 Preoperative prognostic nomogram for metastatic gastric adenocarcinoma patients who undergo gastrectomy. Visceral metastasis is defined as
distant metastasis other than positive distant lymph nodes, carcinomatosis, Krukenberg tumors (metastases to the ovaries), or malignant (tumor cell-
positive) ascites. AJCC, American Joint Committee on Cancer; NOS, not otherwise specified; LN, lymph node
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models were limited to those available in the database.
The database cannot provide more details of the patients,
for example, performance status of the patients, oliogo- or
multi-metastasis of tumor, et al.; as to the information on
treatment, only sequence of radiotherapy with surgery was
displayed in database, other details such as residues of
tumor resection (R0, R1 or R2), chemotherapy sequence
and concurrent chemo-radiation were omitted in current
cohort. All these factors were considered to be have
impact on survival of patients who received palliative
gastrectomy. Finally, constructing the preoperative nomo-
gram depended in part on postoperative parameters such
as T and N staging as surrogates; if more relevant
preoperative parameters been available, they would likely
have been more valuable.
Conclusions
We constructed first-of-their-type nomograms that are
predictive of survival in patients with metastatic gastric
adenocarcinoma who are candidates for palliative gastrec-
tomy. Despite some limitations, these nomograms may as-
sist surgeons in their decision-making regarding treatment
as well as in evaluating their patients’ prognoses.
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